1. Background {#sec101404}
=============

Primary percutaneous coronary intervention (PCI) is a reperfusion strategy used in patients with acute ST-segment elevation myocardial infarction (STEMI), to prevent progression of myocardial necrosis. Besides the advantages of this strategy, there are situations in which myocardial reperfusion does not restore to its optimal level ([@A25414R1]-[@A25414R5]). This condition, known as "no-reflow" phenomenon, happens in several cases ([@A25414R6]). In those cases, even after reopening of infarct-related coronary artery, and while there is no angiographic evidence of mechanical obstruction, optimal myocardial reperfusion is not seen ([@A25414R7]). The no-reflow phenomenon is an uncommon and critical occurrence and, if not reversed, causes a high rate of morbidity and mortality ([@A25414R8]). A study demonstrated that the no-reflow phenomenon after primary PCI is a strong predictor of death extending to up to 5 years after the acute event in patients with STEMI ([@A25414R9]). Several studies investigated predisposing factors of the no-reflow phenomenon. However, at present we know little about clinical predictors of no-reflow after PCI. Considering a steady increase in the use of primary PCI, improving in efficacy of coronary reperfusion after STEMI seems necessary ([@A25414R5]).

2. Objectives {#sec101405}
=============

This study aims to evaluate clinical and procedural predictive factors of the no-reflow phenomenon, following primary PCI.

3. Patients and Methods {#sec101410}
=======================

3.1. Study Population {#sec101406}
---------------------

During an 18-month period, from 2013 to 2014, 438 patients with acute myocardial infarction (AMI), presenting within the first 24 h from symptoms onset, were treated with primary PCI in Rajaie Cardiovascular Medical and Research Center, Tehran, Iran, a tertiary care center for cardiovascular patients. Coronary angiography and primary PCI was performed according to the standard criteria. The thrombolysis in myocardial infarction (TIMI) flow was measured in all patients during the first angiography, following stenting. The no-reflow phenomenon was diagnosed, based on two criteria: 1) reopening of occluded coronary artery and successful stent placement on angiography; 2) TIMI flow grade 0 and 1 on angiography. According to the no-reflow phenomenon definition, in this case-control study, 49 patients were allocated to the case group, based on the no-reflow phenomenon occurred during primary PCI (TIMI grade 0 and 1), and 50 patients without no-reflow phenomenon (TIMI grade ≥ 3) were randomly selected, as control group, who were matched in terms of stenting, stent type, stent size, prescription of glycoprotein IIb/IIIa inhibitors and use of predilation.

3.2. Data Collection, Angiographic Evaluation and Clinical Follow-up {#sec101407}
--------------------------------------------------------------------

Physical examination was performed at the time of admission, by the staff physicians. Duration of pain and a clinical history of risk factors, such as smoking, diabetes mellitus and hypertension were obtained. Laboratory data were gathered using white blood cell (WBC) count and high-sensitivity C-reactive protein (hs-CRP) tests. We did not include patients who had a history of myocardial infarction or received thrombolytic therapy. The exclusion criteria were: 1) presence of mechanical failure; 2) Severe bradycardia or 3rd-degree atrio-ventricular (AV)-block; 3) inadequate quality angiograms. Patients were diagnosed with STEMI if they had chest pain for more than 20 minutes and these changes in electrocardiographs (ECG): ST segment elevated ≥ 1 mm in the limb leads and ≥ 2 mm in the precordial leads in at least two anatomically contiguous leads. All patients underwent coronary angiography and the diagnosis of STEMI was confirmed. Diagnosis of the no-reflow phenomenon and slow-flow was made by reviewing coronary angiographic criteria of CTFC (corrected TIMI frame count). Each patient underwent a 12-lead ECG to investigate ST-changes and then a two-dimensional-echocardiography was performed to determine left ventricle (LV) function. Size of lesion and diameter of target vessel were also measured. With 30 minutes before coronary angiography, all patients received aspirin (325 mg) and clopidogrel (600 mg), orally. Then, all patients received heparin (100 U/kg) and angiography was performed using the right femoral artery approach to investigate the culprit lesion. Bifurcation lesions, eccentricity and coronary anatomy were investigated and the presence of single vessel disease (SVD), two vessel disease (2VD) and three vessel disease (3VD) were recorded. Then, by using balloon catheters of appropriate size, percutaneous transluminal coronary angioplasty (PTCA) was performed. The TIMI thrombus grade, based on the Mehta Strategy for Thrombus Management ([@A25414R10]) was defined as G0 = no thrombus, G1 = possible thrombus, G2 = small \[greatest dimension ≤ 1/2 vessel diameter (VD)\], G3 = moderate (\> 1/2 and \< 2VD), G4 = large (≥ 2VD), G5: total occlusion ([@A25414R11]).

3.3. Inter-Observer Reliability Study {#sec101408}
-------------------------------------

The 20 cases of all patients were randomly selected and assessed for the inter-observer reliability study of TIMI flow before and after PCI. The TIMI flow was determined by the first physician and then repeated by a second observer. The operators were blinded to each other's examination results.

3.4. Statistics {#sec101409}
---------------

Mean value, standard deviation (SD) and frequency were used in the descriptive analysis. For evaluation the distribution of data, one-sample Kolmogorov-Smirnov test was used. Qualitative data were compared with Chi-squared test. Mann Whitney U test was used to compare quantitative variables. Variables that had any relationship with the no-reflow phenomenon were entered into the multivariable logistic regression model, using the backward variable selection method, which was constructed based on significant variables (P \< 0.05) that resulted from the univariate analysis. The Bland-Altman method was used for inter-observer reliability measurement between two observers. The mean determined TIMI flows of these two observers were also compared by paired sample t-test.

4. Results {#sec101415}
==========

4.1. Demographic and Baseline Characteristics Results {#sec101411}
-----------------------------------------------------

Mean age of study population was of 59.47 (SD = 12.48) years. From these patients, 75 (75.8%) were male and 24 (24.2%) were female. Smoking was seen in 20 (20.2%) patients. The case group included 60% (12 patients) of smokers. There were no significant differences between the two groups, according to smoking (P = 0.29). Forty patients (40.4%) had a history of diabetes mellitus, and among them, 20 (50%) patients were in case group. No significant difference was detected in these variables between the two groups (P = 0.93). A total of 27 (27.3%) of patients had hypertension, and 55.6% of them (15 patients) were in the case group. There were no significant differences between two groups, according to hypertension (P = 0.46).

4.2. Laboratory Data Results {#sec101412}
----------------------------

Laboratory data of the study sample are shown in [Table 1](#tbl26108){ref-type="table"}. As can be seen in [Table 1](#tbl26108){ref-type="table"}, there was a significant difference in WBC count and also hs-CRP level between the two groups of our study, while the WBC count and hs-CRP levels were 12982.45 (4635.821) and 51.357 (57.4866), respectively, in case group, and 11223.40 (3413.166) and 12.000 (23.9409), in the control group.

###### Comparison of Laboratory Data in Two Groups ^[a](#fn24822){ref-type="table-fn"}^

  Laboratory Data         Case                   Control              P Value
  ----------------------- ---------------------- -------------------- ---------
  **WBC-count**           1298.45 (4635.82)      11223.40 (3413.16)   0.05
  **Hb-level, g/dL**      14.52 (1.63)           13.94 (1.87)         0.12
  **Plt-count**           224336.73 (72888.85)   229740 (58141.21)    0.65
  **Hs-CRP level**        51.35 (57.48)          12 (23.94)           0.04
  **Creatinine, mg/dL**   1.15 (.66)             1.13 (.99)           0.39
  **GFR, mL/min**         76.24 (23.54)          77.20 (24.22)        0.69
  **FBS, mg/dL**          161.82 (84.61)         163.96 (100.03)      0.60
  **BS-at admission**     182.24 (93.78)         191.88 (112.39)      0.98
  **TG, mg/dL**           130.39 (63.49)         116.05 (46.81)       0.53
  **LDL, mg/dL**          100.18 (33.93)         107.07 (34.07)       0.39
  **HDL, mg/dL**          43.30(9.84)            42.28 (7.58)         0.96

^a^ Abbreviations: BS, Blood sugar; FBS, fasting blood glucose; GFR, glomerular filtration rate; Hb, hemoglobin; HDL-C, high-density lipoprotein cholesterol; Hs-CRP, high sensitivity-CRP; LDL-C, low-density lipoprotein cholesterol; Plt, platelet; TG, triglyceride; and WBC, white blood cell.

4.3. Examination and Angiographic Data Results {#sec101413}
----------------------------------------------

Mean duration of pain was 2.96 (SD = 1.84) hours and mean of maximal ST-change was 3.23 (SD = 1.07) millimeters. Left ventricle function was determined at 35.71% (SD = 10.20) by echocardiography. The mean length of the lesions, which were observed in patients, was 26.31 (SD = 9.99) millimeters and the target vessel diameter was 3.12 (SD = 0.44) millimeters. [Table 2](#tbl26109){ref-type="table"} shows that pain duration and LV function were statistically lower in the case group, while maximal ST-change was higher. Angiography data are depicted in [Table 3](#tbl26110){ref-type="table"}. Thrombus grade was 3.73 (1.35) in cases and 2.70 (1.52) in controls, which was significantly different (P = 0.001). Bifurcation was higher in the case group (six (12.2%)) compared to control group (one (2%)) (P = 0.04). Lesions in 14 (28.6%) cases and five (10%) controls were eccentric (P = 0.01). There were statistically significant differences between the two groups in coronary anatomy (P = 0.001). Most of patients in the case group had 3VD (10 (20.4%)) or 2VD (15 (30.6%)), while 40 patients (80%) in the control group had SVD. Two vessel diseases were seen in 10 (20%) members of the control group. We used multivariable logistic regression test to determine predictors of no- reflow following primary PCI. Based on univariable analysis, WBC count, pain duration, LV function, maximal ST-change, thrombus graded and eccentricity were identified as predictors of the no-reflow phenomenon. After multivariable logistic regression, using backward variable selection method analysis, WBC count and thrombus grade remained as significant independent predictors of the no-reflow phenomenon (P \< 0.05) ([Table 4](#tbl26111){ref-type="table"}).

###### Differences in Pain-Duration, Maximal ST-Change, LV-Function, Lesion Length and Target Vessel Diameter Between the two Groups of our Study ^[a](#fn24823){ref-type="table-fn"}^

  Group                            Mean ± SD       P Value
  -------------------------------- --------------- ----------
  **Pain-duration, h**                             \< 0.001
  Case                             2.31 ± 1.37     
  Control                          3.60 ± 2.02     
  **Maximal ST-change, mm**                        0.004
  Case                             3.55 ± 1.15     
  Control                          2.92 ± 0.90     
  **LV-function, %**                               0.005
  Case                             32.65 ± 10.26   
  Control                          38.70 ± 9.30    
  **Lesion length, mm**                            0.52
  Case                             26.43 ± 9.19    
  Control                          26.20 ± 10.81   
  **Target vessel diameter, mm**                   0.41
  Case                             3.16 ± 0.48     
  Control                          3.09 ± 0.40     

^a^ Abbreviation: LV, left ventricle.

###### Comparison of Angiographic Characteristics Between the two Groups ^[a](#fn24824){ref-type="table-fn"},[b](#fn24825){ref-type="table-fn"}^

  Characteristic             Case            Control        P Value
  -------------------------- --------------- -------------- ----------
  **Thrombus grade**         3.73 (1.35)     2.70 (1.52)    0.001
  **TIMI-flow before PCI**   0.57 (0.86)     0.30 (0.64)    0.89
  **TIMI-flow after PCI**    1.86 (.35)      3 (0)          \< 0.001
  **CTFC**                   34.94 (10.32)   18.28 (4.03)   \< 0.001
  **Infarction territory**                                  0.80
  Ant-MI                     31 (63.3)       30 (60)        
  Inf-MI                     14 (28.6)       17 (34)        
  Lat-MI                     4 (8.2)         3 (6)          
  **Culprit vessel**                                        0.52
  LAD                        30 (61.2)       30 (60)        
  LCX                        4 (8.2)         5 (10)         
  RCA                        13 (26.5)       15 (30)        
  Graft                      2 (4.1)         0 (0)          
  **Bifurcation lesion**                                    0.04
  No                         43 (87.8)       49 (98)        
  Yes                        6 (12.2)        1 (2)          
  **Pre dilation**                                          0.36
  No                         23 (46.9)       28 (56)        
  Yes                        26 (53.1)       22 (44)        
  **Post dilation**                                         0.23
  No                         40 (81.6)       45 (90)        
  Yes                        9 (18.4)        5 (10)         
  **Thrombus aspiration**                                   0.55
  No                         25 (52.1)       29 (58)        
  Yes                        23 (47.9)       21 (42)        
  **Lesion eccentricity**                                   0.01
  Concentric                 35 (71.4)       45 (90)        
  Eccentric                  14 (28.6)       5 (10)         
  **Lesion angulation**                                     0.55
  Straight                   32 (65.3)       34 (69)        
  Angulated                  17 (34.7)       16 (32)        
  **Location of lesion**                                    0.44
  Proximal                   26 (53.1)       30 (60)        
  Mid part                   15 (30.6)       16 (32)        
  Distal                     8 (16.3)        4 (8)          
  **Coronary anatomy**                                      0.001
  SVD                        24 (49)         40 (80)        
  2VD                        15 (30.6)       10 (20)        
  3VD                        10 (20.4)       0 (0)          
  **Tortuosity**                                            0.59
  Mild                       45 (91.8)       47 (94)        
  Moderate                   3 (6.1)         3 (6)          
  Sever                      1 (2)           0 (0)          
  **Number of stent**                                       0.11
  0                          3 (6.1)         1 (2)          
  1                          43 (87.8)       42 (84)        
  2                          3 (6.1)         7 (14)         
  **In-stent thrombosis**                                   0.67
  No                         45 (91.8)       47 (94)        
  Yes                        4 (8.2)         3 (6)          

^a^ Abbreviations: Ant-MI, anterior myocardial infarction; Inf-MI, inferior myocardial infarction; LAD, left anterior descending coronary artery; Lat-MI, lateral myocardial infarction; LCX, left circumflex coronary artery; PCI, percutaneous coronary intervention; CTFC, corrected TIMI frame count; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.

^b^ data are presented as No. (%).

###### Multivariable Logistic Regression Based on Backward Logistic Regression Method ^[a](#fn24826){ref-type="table-fn"}^

  Variables               Coefficient   P Value   OR (CI 95%)
  ----------------------- ------------- --------- --------------------
  **WBC**                 0.517         0.003     1.67 (1.19 - 2.35)
  **Thrombus graded**     \- 0.46       0.01      0.67 (0.43 - 0.89)
  **Eccentricity**        \- 1.16       0.10      0.10 (0.07 - 1.26)
  **Maximal ST-Change**   \- 0.425      0.08      0.65 (0.40 - 1.05)

^a^ Abbreviations: OR: Odds Ratio; WBC, white blood cell count.

4.4. Inter Observer Reliability {#sec101414}
-------------------------------

Bland and Altman method showed there were no statistically significant differences between determined TIMI flow before PCI (P = 0.57) and after PCI (P = 0.57) by two observers. Mean of differences of TIMI flow for two observers before PCI was -0.5 ± 0.39 (mean of differences ± 2, SD = -1.28 - 0.28). Mean of differences between two observed flows after PCI was 0.5 ± 0.39 (mean of differences ± 2, SD was -0.28 - 1.28).

5. Discussion {#sec101416}
=============

We found that the predictive factors of the no-reflow phenomenon in AMI patients undergoing primary PCI are: WBC count and thrombus grade. Also, there is an association between developing the no-reflow phenomenon and pain duration, maximal ST-changes, LV function, hs-CRP, bifurcation, eccentricity and coronary anatomy. Pain duration was shorter in the case group. The shorter pain duration, the fresher the clot in the artery would be. Therefore, fresh clot increases the risk of occurrence of the no-reflow phenomenon in AMI patients after PCI. Zalewski et al. ([@A25414R12]) demonstrated that altered clot properties may characterize patients with the no-reflow phenomenon and might help identify subjects at increased risk of such a complication. Iwakura et al. ([@A25414R13]) reported that a short duration pain before the onset of AMI, translates into attenuation of the size of the infarction area, which results in better cardiac function recovery after PCI. Komamura et al. ([@A25414R14]) studied the changes in coronary vein flow in AMI patients and concluded that pre-infarction angina reduces the decrease in coronary flow, which helps the reperfusion after thrombolysis. Left ventricle ejection fraction (LVEF) was lower in patients with no-reflow phenomenon. This can be explained by the severity of coronary lesion and occlusion, and subsequently, more damage to the myocardium in case group. Ndrepepa et al. ([@A25414R5]) reported worse LVEF at 6 months, in patients with the no-reflow phenomenon, in comparison with the control group. Other studies also demonstrated that, based on follow up studies, no-reflow phenomenon causes malignant arrhythmias, reduced ejection fraction, and increases risk of cardiac death ([@A25414R11], [@A25414R15]). The WBC count was higher in patients with the no-reflow phenomenon, which may be due to increased inflammation and aggregation of WBC in artery and myocardium. This increases the possibility of the no-reflow phenomenon. The existence of more bifurcations in the no-reflow phenomenon patients indicates more complex lesions, and therefore requires complex procedures ([@A25414R6]). Thrombus grade was another predictive factor of the no-reflow phenomenon, which was higher in the case group. An increased clot volume causes higher thrombus grade and subsequently increases the possibility of no-reflow phenomenon ([@A25414R16]). Logistic regression in this study shows that WBC count and thrombus grade are independent predictive factors of developing no-reflow phenomenon. It seems that more factors that were not investigated in our study can predict the development of the no-reflow phenomenon in AMI. Iwakura et al. ([@A25414R13]) reported the number of abnormal Q-waves and the wall motion score as independent predictive factors. Larger infarct size is another predictive factor, which was evaluated in different studies ([@A25414R5], [@A25414R9], [@A25414R17]). We had limitations while performing the study. The presence of pre-infarction angina was checked only through patients' records of clinical history, where silent ischemia could not be evaluated. We did not assess the effect of drugs that patients received during pre-infarction period. The WBC count and thrombus grade are strong, independent predictive factors of developing the no-reflow phenomenon in AMI patients undergoing primary PCI. There is also an association between the no-reflow phenomenon and pain duration, maximal ST-change, LV function, hs-CRP, bifurcation, eccentricity and coronary anatomy. Better prediction of no-reflow phenomenon would help us to conduct measures to prevent this phenomenon and reduce the subsequent complications. Further studies, focusing on the effect of drugs received during the pre-infarction period, and follow up of the patients are suggested.
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